{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:42:09Z","timestamp":1790700129284,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The therapeutic effect of bumetanide on autism spectrum disorder (ASD) seems to be controversial. To obtain better evidence on the efficacy of bumetanide, a systematic review and meta-analysis were performed.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Randomized, placebo-controlled trials (RCTs) of bumetanide treatment in children with ASD were identified through systematic review from database inception to January 17, 2021. Subsequently, a meta-analysis was carried out to examine the effect of bumetanide on the severity of symptoms of ASD as assessed by the Childhood Autism Rating Scale (CARS) and Social Responsive Scale (SRS); core symptoms according to criteria of the <jats:italic>Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic> (DSM)-5 of the American Psychiatric Association [social affect (SA), restricted, repetitive patterns of behavior, interests, or activities (RRB) and sensory symptoms]; and the therapeutic effect as assessed by Clinical Global Impressions-Efficacy (CGI-E).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, six RCTs involving 496 participants with ASD were identified in our study. The results showed that bumetanide could significantly improve the severity of the ASD symptoms measured by CARS and SRS. There was also evidence that bumetanide had positive effect on the core symptoms of ASD such as the SA and RRB, but there was no statistically significant effect on sensory symptoms. A significant positive effect on CGI-E scores in ASD patients was also observed.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our meta-analysis provided some support that bumetanide could improve the symptoms of children with ASD. However, additional large-scale longitudinal studies that provide clearer information and better control for confounding factors are needed to confirm our findings.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.751575","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T05:01:42Z","timestamp":1636952502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment Effect of Bumetanide in Children With Autism Spectrum Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Tiantian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyue","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6904a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years \u2013 Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2016","volume":"69","author":"Maenner","year":"2020","journal-title":"MMWR Surveill Summ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0140-6736(18)31129-2","article-title":"Autism spectrum disorder","volume":"392","author":"Lord","year":"2018","journal-title":"Lancet."},{"key":"B3","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","year":"2013"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J Autism Dev Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e18661","DOI":"10.1097\/MD.0000000000018661","article-title":"clinical application of vitamin D and bumetanide in children with autism spectrum disorder: a case report","volume":"99","author":"Feng","year":"2020","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","article-title":"The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects","volume":"99","author":"Lemonnier","year":"2010","journal-title":"Acta Paediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fped.2014.00070","article-title":"GABAergic signaling as therapeutic target for autism spectrum disorders","volume":"2","author":"Cellot","year":"2014","journal-title":"Front Pediatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fnhum.2017.00354","article-title":"Neurodevelopmental hypothesis about the etiology of autism spectrum disorders","volume":"11","author":"Inui","year":"2017","journal-title":"Front Hum Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neubiorev.2018.05.001","article-title":"Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions","volume":"90","author":"Schulte","year":"2018","journal-title":"Neurosci Biobehav Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fncel.2016.00090","article-title":"Failure of the Nemo trial: bumetanide is a promising agent to treat many brain disorders but not newborn seizures","volume":"10","author":"Ben-Ari","year":"2016","journal-title":"Front Cell Neurosci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","article-title":"NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders","volume":"40","author":"Ben-Ari","year":"2017","journal-title":"Trends Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41398-018-0155-1","article-title":"Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models","volume":"8","author":"Horder","year":"2018","journal-title":"Transl Psychiatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/brain\/awr041","article-title":"Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital","volume":"134","author":"Nardou","year":"2011","journal-title":"Brain."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1542\/peds.2014-4133","article-title":"Paradoxical benzodiazepine response: a rationale for bumetanide in neurodevelopmental disorders?","volume":"136","author":"Bruining","year":"2015","journal-title":"Pediatrics."},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13229-020-00335-4","article-title":"Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study","volume":"11","author":"Van Andel","year":"2020","journal-title":"Mol Autism."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/tp.2012.124","article-title":"A randomised controlled trial of bumetanide in the treatment of autism in children","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Transl Psychiatr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1124","DOI":"10.1038\/tp.2017.101","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl Psychiatr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.18.20197640","article-title":"Improved symptoms following bumetanide treatment in children aged 3 to 6 years with autism spectrum disorder via GABAergic mechanisms: a randomized, double-blind, placebo-controlled trial","author":"Dai","year":"2020","journal-title":"medRxiv [Preprint]."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/apa.15723","article-title":"Bumetanide for autism: open-label trial in six children","volume":"110","author":"Fernell","year":"2020","journal-title":"Acta Paediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","article-title":"Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl Psychiatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1362361313514141","article-title":"Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study","volume":"19","author":"Hadjikhani","year":"2015","journal-title":"Autism."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1038\/s41598-018-21958-x","article-title":"Bumetanide for autism: more eye contact, less amygdala activation","volume":"8","author":"Hadjikhani","year":"2018","journal-title":"Sci Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"bcr2013202092","DOI":"10.1136\/bcr-2013-202092","article-title":"The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome","volume":"2014","author":"Grandgeorge","year":"2014","journal-title":"BMJ Case Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial","volume":"60","author":"Sprengers","year":"2020","journal-title":"J Am Acad Child Adolesc Psychiatr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/cap.2015.0045","article-title":"A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism","volume":"25","author":"Du","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaac.2020.03.007","article-title":"Meta-analysis: pharmacologic treatment of restricted and repetitive behaviors in autism spectrum disorders","volume":"60","author":"Zhou","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.32598\/bcn.9.10.380","article-title":"Bumetanide therapeutic effect in children and adolescents with autism spectrum disorder: a review study","volume":"10","author":"Mollajani","year":"2019","journal-title":"Basic Clin Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/1060028018817304","article-title":"Bumetanide for autism spectrum disorder in children: a review of randomized controlled trials","volume":"53","author":"James","year":"2019","journal-title":"Ann Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13229-017-0166-4","article-title":"Testing the excitation\/inhibition imbalance hypothesis in a mouse model of the autism spectrum disorder: in vivo neurospectroscopy and molecular evidence for regional phenotypes","volume":"8","author":"Gon\u00e7alves","year":"2017","journal-title":"Mol Autism."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.751575\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T05:01:45Z","timestamp":1636952505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.751575\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":30,"alternative-id":["10.3389\/fpsyt.2021.751575"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.751575","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"article-number":"751575"}}